Appendix 3: Supplementary figures [posted as supplied by author]

 $\textbf{Fig A:} \ \textbf{Methodological quality of the randomized controlled trials}$

| | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias): Clinical outcomes | Blinding of outcome assessment (detection bias): Pharmacokinetic outcomes | Incomplete outcome data (attrition bias): Clinical outcomes | Incomplete outcome data (attrition bias): Pharmacokinetic outcomes | Selective reporting (reporting bias) | Other bias |
|----------------------------|---|---|---|--|---|---|--|--------------------------------------|------------|
| Abdallah 2010 (75) | ? | ? | • | ? | ? | ? | ? | ? | |
| Alloway 2012 (63) | ? | ? | • | ? | ? | + | + | + | + |
| David-Neto 2004 (34) | + | ? | ? | | ? | | + | + | |
| First 1998 (58) | ? | ? | ? | ? | ? | + | + | + | |
| Fisher 1999 (59) | ? | ? | + | ? | ? | ? | ? | - | + |
| Hibberd 2006 (38) | ? | ? | • | | ? | | + | + | |
| Khatami 2013 (62) | + | + | + | ? | ? | • | • | + | |
| Kim 1998 (40) | ? | ? | ? | ? | ? | ? | ? | + | |
| Leet 2009 (42) | ? | ? | • | ? | ? | + | + | + | + |
| Masri 1996 (61) | ? | ? | ? | ? | ? | ? | ? | + | |
| Min 2013 (68) | + | ? | • | ? | ? | • | • | + | |
| Qazi 2006 (47) | ? | ? | ? | ? | ? | + | + | + | |
| Robertsen 2014 (74) | + | + | | | ? | | + | + | + |
| | ? | ? | ? | ? | ? | + | + | + | |
| Stephan 1998 (52) | 1000 | | | ? | ? | + | + | + | |
| Sunder-Plassmann 2012 (78) | ? | ? | | | | | | | |
| | ? | ? | ? | ? | ? | + | + | + | |

Fig B: Neoral serum creatinine kidney RCTs

| | N | leoral | | Generic cyclosporine | | | | Mean Difference | Mean Difference | | | |
|---|--------|--------|-------|----------------------|-------|-------|--------|----------------------|---|--|--|--|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | | | |
| Khatami 2013 (62) | 117.5 | 53 | 110 | 107.8 | 17.6 | 111 | 46.6% | 9.70 [-0.73, 20.13] | | | | |
| Masri 1996 (61) | 140.56 | 35.36 | 21 | 129.06 | 29.17 | 23 | 13.7% | 11.50 [-7.76, 30.76] | | | | |
| Stephan 1998 (52) | 107.85 | 21.22 | 20 | 106.96 | 18.56 | 32 | 39.7% | 0.89 [-10.42, 12.20] | | | | |
| Total (95% CI) | | 2 | 151 | | 2 | | 100.0% | 6.45 [-0.67, 13.57] | • | | | |
| Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 1.57$, $df = 2$ ($P = 0.46$); $I^2 = 0\%$ Test for overall effect: $Z = 1.77$ ($P = 0.08$) | | | | | | | | | -50 -25 0 25 50 Favours [Neoral] Favours [generic] | | | |